Genzyme R&D is affected big time, this was expected and rumored about for a while now. The number is in low sixties and will stay there. Strategic R&D took the biggest hit. Let's hope this is it. I am not sure if Sanofi is cutting staff in other areas, it's my understanding they are after R&D this time, so anything can happen. It's a sad day for all of us, some amazing talent was lost. Good luck to all!